Getinge AB ser. B
Research Getinge AB ser. B (GETI-B) on Bullrun: valuation model: 7.1% undervalued, market cap SEK 66.54B, P/E 24.9, dividend yield 1.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGETI-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Valuation signal7.1% undervalued
- Market capSEK 66.54B
- P/E24.9
- Dividend yield1.9%
- Financial periodQ2 2026
- RevenueSEK 8.38B
- Net incomeSEK 841.00M
- Free cash flowSEK 995.00M
- Gross margin52.7%
Valuation Snapshot
Bullrun's latest valuation model marks Getinge AB ser. B as 7.1% undervalued; latest market cap is SEK 66.54B; P/E is 24.9; dividend yield is 1.9%.
Peer valuation comparison
Latest P/E is 24.87x versus a Healthcare sector median of 24.46x.
Latest dividend yield is 1.92% versus a Healthcare sector median of 2.11% (9.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 34.97B | SEK 2.26B | n/a | 47.6% | n/a | SEK 3.40B | SEK 10.88B | SEK 29.43B |
| FY2024 | SEK 34.76B | SEK 1.65B | n/a | 46.5% | 6.01 | SEK 2.96B | SEK 8.93B | SEK 33.01B |
| FY2023 | SEK 31.83B | SEK 2.43B | n/a | 45.5% | 8.86 | SEK 2.73B | SEK 6.60B | SEK 30.17B |
| FY2022 | SEK 28.29B | SEK 2.52B | n/a | 47.4% | 9.15 | SEK 5.68B | SEK 4.51B | SEK 30.45B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 66.54B | 24.9 | 1.9% | 4.75 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 4.75 SEK, yield 1.9%.
| Year | Dividends/share |
|---|---|
| FY2024 | 4.4 SEK |
| FY2023 | 4.25 SEK |
| FY2022 | 4 SEK |
About Getinge AB ser. B
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Getinge AB ser. B overvalued or undervalued?
Bullrun's valuation model currently marks Getinge AB ser. B as 7.1% undervalued.
What is Getinge AB ser. B's market cap?
Getinge AB ser. B's market capitalization is SEK 66.54B.
What is Getinge AB ser. B's P/E ratio?
Getinge AB ser. B's price-to-earnings (P/E) ratio is 24.9.
Does Getinge AB ser. B pay a dividend?
Getinge AB ser. B has a dividend yield of 1.9%.
What does Getinge AB ser. B do?
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions.